DAVID ALTSHULER - 17 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Feb 2023
Net transactions value
-$2,273,864
Form type
4
Filing time
22 Feb 2023, 15:25:25 UTC
Previous filing
16 Feb 2023
Next filing
28 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $1,098,188 -3,750 -7.8% $292.85 44,248 17 Feb 2023 Direct
transaction VRTX Common Stock Sale $10,476 -36 -0.08% $291.01 44,212 21 Feb 2023 Direct F1
transaction VRTX Common Stock Sale $358,045 -1,223 -2.8% $292.76 42,989 21 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $541,897 -1,843 -4.3% $294.03 41,146 21 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $265,257 -900 -2.2% $294.73 40,246 21 Feb 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $292.76 (range $292.25 to $293.12).
F4 Open market sales reported on this line occurred at a weighted average price of $294.03 (range $293.45 to $294.42).
F5 Open market sales reported on this line occurred at a weighted average price of $294.73 (range $294.47 to $295.37).